Table 1.

Baseline patient characteristics by number of KDOQI guideline goals achieved at hemodialysis initiation

Baseline CharacteristicsTotalNumber of Guideline Goals Meta
0123
n192,307113,60558,94916,6413112
Age (mean ± SD)64 ± 1563 ± 1565 ± 1565 ± 1465 ± 15
Women, n (%)85,228 (44)52,509 (46)25,129 (43)6475 (39)1115 (36)
Race, n (%)
    White124,875 (65)71,965 (63)39,161 (66)11,459 (69)2290 (74)
    African American57,293 (30)35,891 (32)16,528 (28)4231 (25)643 (21)
    Asian7762 (4.0)4280 (3.7)2562 (4.4)762 (4.6)158 (5.3)
    Native American2112 (1.2)1310 (1.2)613 (1.5)170 (1.3)19 (0.6)
    Other265 (0.1)159 (0.1)85 (0.1)19 (0.1)2 (0.1)
Cause of ESRD, n (%)
    Diabetes89,179 (46)53,328 (47)27,575 (47)7269 (44)1007 (32)
    Hypertension54,339 (28)30,967 (27)17,163 (29)5116 (31)1093 (35)
    Glomerulonephritis12,203 (6.4)6618 (5.8)3881 (7)1396 (8.4)308 (10)
    Other36,586 (19)22,692 (20)10,330 (18)2860 (17)704 (23)
Comorbid conditions, n (%)
    ASHD44,389 (23)25,680 (23)14,194 (24)3823 (23)692 (22)
    CHF68,138 (35)42,340 (37)20,714 (35)4489 (27)595 (19)
    PVD29,540 (15)17,779 (16)9097 (15)2289 (14)375 (12)
    CVA/TIA19,861 (10)11,660 (10)6317 (11)1635 (10)249 (8)
Functional status
    ADL help, n (%)22,175 (12)14,638 (13)6325 (11)1096 (6.6)116 (3.7)
    Institutionalized, n (%)15,655 (8)10,617 (9)4342 (7)637 (3.8)59 (1.9)
    Employed, n (%)18,121 (9)9892 (9)5641 (10)2067 (12)521 (17)
BMI (mean ± SD)28.6 ± 7.728.6 ± 7.828.5 ± 7.628.7 ± 7.328.2 ± 6.6
eGFR (mean ± SD)10.5 ± 4.910.4 ± 5.010.8 ± 4.810.6 ± 4.310.5 ± 3.9
Erythropoietin use, n (%)56,744 (30)26,269 (23)20,654 (35)8078 (49)1743 (56)
Predialysis nephrology care, n (%)
    0 to 12 months66,616 (35)35,609 (31)22,571 (38)7153 (43)1283 (41)
    >12 months41,747 (22)17,939 (16)15,442 (26)6759 (41)1607 (52)
    None61,542 (32)44,861 (40)14,831 (25)1730 (10)120 (3.9)
    Missing22,402 (12)15,196 (13)6105 (10)999 (6.0)102 (3.3)
Predialysis dietitian care, n (%)
    0 to 12 months13,327 (6.9)6059 (5.3)4827 (8.2)2026 (12)415 (13)
    >12 months4913 (2.6)1764 (1.6)1842 (3.1)1029 (6.2)277 (8.9)
    None138,200 (72)84,120 (74)41,385 (70)10,761 (65)1934 (62)
    Missing35,867 (19)21,661 (19)10,895 (19)2825 (17)486 (16)
Hemoglobin (mean ± SD, g/dl)10.1 ± 1.79.2 ± 1.211.0 ± 1.711.7 ± 1.312.2 ± 0.9
Albumin (mean ± SD, g/dl)3.1 ± 0.72.9 ± 0.63.2 ± 0.73.7 ± 0.64.2 ± 0.3
Access at initiation, n (%)
    Arteriovenous fistula25,394 (13)NA13,425 (23)9413 (57)2556 (82)
    Arteriovenous graft8462 (4.4)NA5199 (8.8)2707 (16)556 (18)
    Catheter156,014 (81)111,902 (99)39,688 (67)4424 (27)NA
    Other2305 (1.2)1615 (1.4)598 (1.0)92 (0.6)NA
    Missing132 (0.1)88 (0.1)39 (0.1)5 (0)NA
    Maturing33,312 (17)22,190 (19)9486 (16)1599 (10)97 (3.1)
    Arteriovenous graft maturing7747 (4.0)4673 (4.1)2385 (4.1)592 (3.6)37 (1.2)
  • ADL, activities of daily living; ASHD, atherosclerotic heart disease; BMI, body mass index; CHF, congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; eGFR, estimated GFR in ml/min per 1.73 m2; ESRD, end-stage renal disease; NA, not applicable; PVD, peripheral vascular disease.

  • a All P 0.001 for comparisons between groups.